

Grifols, S.A.

Avinguda de la Generalitat 152-158 08174 Sant Cugat del Vallès Barcelona - ESPAÑA

Tel. [34] 935 710 500 Fax [34] 935 710 267 www.grifols.com

Grifols, S.A. ("Grifols"), in accordance with the provisions of article 227 of the Consolidated Text of the Securities Market Act, approved by the Legislative Royal Decree 4/2015, of 23 October, reports the following

## OTHER RELEVANT INFORMATION

Grifols has executed a 15 year long-term renewable collaboration agreement with Canadian Blood Services, a non-profit organization in Canada that operates with a national scope, infrastructure and governance within the Canadian healthcare system in the domain of blood, plasma, stem cells, organs and tissues, providing services for patients on behalf of all provincial and territorial governments except Quebec, safeguarding Canada's national system to provide lifesaving therapies ("CBS"). By means of this agreement Grifols has committed to supply an amount of immunoglobulin (*Ig*) to CBS that is equivalent to 25% (2.4M gr.) of Canadian national consumption patient needs, excluding Quebec. Such amount of product will be made available by Grifols to CBS exclusively through the collection of Canadian plasma from a tobe-developed Canadian plasma center collection network and manufactured through a newly Grifols built facility in Canada (Montreal, Quebec).

In addition, from each liter of Canadian plasma used for the provision of *Ig*, Grifols will also supply to CBS all remaining manufactured paste for the processing of other plasma derived products.

Grifols has committed to have the plasma collection network fully developed and ramped-up by July 2026 and a fully operational fractionation facility in Montreal sometime in 2026.

Over the life of the 15-year renewable contract, *Ig* pricing will be in line with Western market values and subject to periodic reviews.

With this collaboration, Grifols demonstrates global leadership forging alliances between the plasma industry and the public sector as the best way to ensure domestic plasma self-sufficiency to provide national security and, thus, guarantee the provision of life-saving products and therapies to patients in Canada.

In Barcelona, on 7 September 2022

Nuria Martín Barnés Secretary to the Board of Directors